专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08598185B2 Unitary pharmaceutical dosage form 有权
公开(公告)号：US08598185B2
公开(公告)日：2013-12-03
申请号：US11453122
申请日：2006-06-13
申请人： Terrence C. Dahl , Munir A. Hussain , Robert A. Lipper , Robert L. Jerzewski , Mark M. Menning , Reza Oliyai , Taiyin Yang
发明人： Terrence C. Dahl , Munir A. Hussain , Robert A. Lipper , Robert L. Jerzewski , Mark M. Menning , Reza Oliyai , Taiyin Yang
IPC分类号： A61K31/551 , A61K31/522 , A61K31/513
CPC分类号： A61K31/683 , A61K9/2054 , A61K9/2077 , A61K9/209 , A61K31/513 , A61K31/522 , A61K31/535 , A61K31/536 , A61K31/551 , A61K31/675
摘要： In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.

2. 发明授权

US06649187B2 Use of polyalkylamine polymers in controlled release devices 失效
公开(公告)号：US06649187B2
公开(公告)日：2003-11-18
申请号：US10074385
申请日：2002-02-12
申请人： Munir A. Hussain , Arnold J. Repta
发明人： Munir A. Hussain , Arnold J. Repta
IPC分类号： A61K924
CPC分类号： A61K31/496 , A61K9/0004 , A61K9/2031
摘要： The invention provides a method and device for administering an amine drug, such as [S-(R,S)]-2-[4-[[(4-methyl)piperazin-1-yl]carbonyl]phenoxy]-3,3-diethyl-N-[1-(3,4-methylenedioxyphenyl)butyl]-4-oxo-1-azetidinecarboxamide), in a sustained release dosage form. The invention includes a pharmaceutical composition and dosage form containing a polyalkylamine polymer and an amine drug. The polyalkylamine polymer is a hydrogel that forms hydrated particles when exposed to an aqueous environment. When mixed with the amine drug in the core of a coated tablet, the polyalkylamine polymer controls the release of the amine drug into an aqueous environment of use. The hydrated particles of the polymer together with the amine drug are released from the tablet core through plural apertures in the surrounding coat.

3. 发明授权

US4673679A Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration 失效
标题翻译：使用3-羟基吗啡喃的前药可防止颊，鼻或舌下给药引起的苦味
公开(公告)号：US4673679A
公开(公告)日：1987-06-16
申请号：US863045
申请日：1986-05-14
申请人： Bruce J. Aungst , Munir A. Hussain
发明人： Bruce J. Aungst , Munir A. Hussain
IPC分类号： C07D221/28 , A61K9/00 , A61K31/47 , A61K31/485 , A61P3/04 , A61P25/04 , A61P25/30 , C07D489/08 , A61K31/44
CPC分类号： A61K9/006 , A61K31/485 , Y10S514/812 , Y10S514/969
摘要： Aliphatic, aromatic, carbonate, carbamate, or sulfonate ester prodrugs of 3-hydroxymorphinans lack the bitter taste of the parent compounds and provide enhanced bioavailability of 3-hydroxymorphinans from buccal, nasal, and sublingual dosage forms.
摘要翻译： 3-羟基吗啡喃的脂肪族，芳香族，碳酸根，氨基甲酸酯或磺酸酯前药缺乏母体化合物的苦味，并且从口腔，鼻和舌下剂型提供3-羟基吗啡喃的增强的生物利用度。

4. 发明授权

US06185453B2 Iontophoretic delivery of integrin inhibitors 失效
标题翻译：整合素抑制剂的离子电渗传递
公开(公告)号：US06185453B2
公开(公告)日：2001-02-06
申请号：US08877829
申请日：1997-06-18
申请人： Munir A. Hussain , Arnold J. Repta
发明人： Munir A. Hussain , Arnold J. Repta
IPC分类号： A61N130
CPC分类号： A61K31/4545 , A61K9/0009 , A61K31/42 , A61K31/4439 , A61N1/0428 , A61N1/0436 , A61N1/0448
摘要： This invention relates to novel methods and devices for iontophoretically administering therapeutic doses of integrin receptor antagonists in a controlled manner through the skin. Such integrin receptor antagonists include but are not limited to antagonists of the IIb/IIIa and &agr;v&bgr;3 integrins and related cell surface adhesive protein receptors. The present invention includes iontophoretic delivery devices comprising integrin inhibitors. Such methods and devices are useful, alone or in combination with other therapeutic agents, for the treatment of thromboembolic disorders, angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.
摘要翻译：本发明涉及以受控方式通过皮肤离子电渗治疗施用治疗剂量的整联蛋白受体拮抗剂的新方法和装置。这样的整联蛋白受体拮抗剂包括但不限于IIb / IIIa和alphavbeta3整联蛋白和相关的细胞表面粘附蛋白受体的拮抗剂。本发明包括包含整联蛋白抑制剂的离子电渗疗法递送装置。这些方法和装置单独或与其它治疗剂组合用于治疗血栓栓塞障碍，血管生成障碍，炎症，骨退化，癌转移，糖尿病性视网膜病变，再狭窄，黄斑变性和由细胞粘附介导的其它病症， /或细胞迁移和/或血管生成。

5. 发明授权

US4965066A Intranasal administration of 3,3-disubstituted indolines 失效
标题翻译：鼻内给药3,3-二取代的吲哚啉
公开(公告)号：US4965066A
公开(公告)日：1990-10-23
申请号：US362284
申请日：1989-06-06
申请人： Munir A. Hussain
发明人： Munir A. Hussain
IPC分类号： A61K9/08 , A61K9/00 , A61K31/40 , A61K31/44 , A61K31/4427 , A61P25/18 , C07D401/06
CPC分类号： A61K9/0043 , A61K31/44
摘要： There is disclosed intranasal pharmaceutical compositions of 3,3-disubstituted indolines useful for treating cognitive or neurological dysfunction in a mammal. Also disclosed is a method of treating cognitive neurological dysfunction in a mammal comprising administering intranasally to the mammal, the 3,3-disubstituted indolines of formula (I).
摘要翻译：公开了可用于治疗哺乳动物的认知或神经功能障碍的3,3-二取代的吲哚啉的鼻内药物组合物。还公开了一种治疗哺乳动物的认知神经功能障碍的方法，其包括向哺乳动物鼻内施用式（I）的3,3-二取代的吲哚啉。

6. 发明授权

US06214834B1 Integrin inhibitor prodrugs 失效
标题翻译：整联蛋白抑制剂前药
公开(公告)号：US06214834B1
公开(公告)日：2001-04-10
申请号：US09049305
申请日：1998-03-27
申请人： Prabhakar K. Jadhav , Douglas G. Batt , Munir A. Hussain , William J. Pitts , Arnold J. Repta
发明人： Prabhakar K. Jadhav , Douglas G. Batt , Munir A. Hussain , William J. Pitts , Arnold J. Repta
IPC分类号： C07D23156
CPC分类号： C07D401/12 , C07D403/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04
摘要： This invention relates to novel heterocycles which are useful as antagonists of the &agr;v&bgr;3 integrin and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, to iontophoretic delivery of such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.
摘要翻译：本发明涉及可用作αphavbeta3整联蛋白和相关细胞表面粘附蛋白受体的拮抗剂的新型杂环，含有这些化合物的药物组合物，这些化合物的离子电渗疗法，以及单独或与用于抑制细胞粘附，血管生成障碍的治疗，炎症，骨退化，癌症转移，糖尿病性视网膜病变，血栓形成，再狭窄，黄斑变性和由细胞粘附和/或细胞迁移介导的其它病症和/或血管生成。

7. 发明授权

US6095326A Packaging of disposable gloves with consumer tissue products 失效
标题翻译：用消费纸巾包装一次性手套
公开(公告)号：US6095326A
公开(公告)日：2000-08-01
申请号：US337721
申请日：1999-06-21
申请人： Maher N. Madhat , Munir A. Hussain
发明人： Maher N. Madhat , Munir A. Hussain
IPC分类号： A61B19/04 , B65D83/08 , B65D71/00
CPC分类号： B65D83/0805 , A61B42/40 , B65D2571/00925
摘要： Packaging of disposable gloves with consumer tissue products in order: To provide first aid protection (disposable gloves) in every type of package of consumer tissue products, and To utilize the widely used consumer tissue products as a vehicle to deliver the disposable gloves to end user. A new package form for consumer tissue products and particularly facial tissue for containing infectious body fluids resulting from the said injuries comprising: a) Any form of consumer package tissue products, b) One or more protective disposable gloves, c) Said gloves package having dimensions allowing said package to be incorporated in any existing forms and shapes of consumer tissue products and particularly facial tissue.
摘要翻译：用消费纸巾产品包装一次性手套：在每种类型的消费纸巾产品包装中提供急救保护（一次性手套），并将广泛使用的消费纸巾产品用作车辆，将一次性手套交付给终端用户。一种用于消费纸巾产品和特别是用于容纳由所述损伤产生的感染性体液的面巾纸的新包装形式，包括：a）任何形式的消费包装纸制品，b）一种或多种保护性一次性手套，c）所述手套包装具有尺寸允许所述包装以任何现有形式和形状的消费纸巾产品，特别是面巾纸结合。

8. 发明授权

US5961483A Iontophoretic delivery of cell adhesion inhibitors 失效
标题翻译：离子电渗传递细胞粘附抑制剂
公开(公告)号：US5961483A
公开(公告)日：1999-10-05
申请号：US878493
申请日：1997-06-18
申请人： Burton H. Sage , Carl Randolph Bock , Philip G. Green , Munir A. Hussain , Arnold J. Repta
发明人： Burton H. Sage , Carl Randolph Bock , Philip G. Green , Munir A. Hussain , Arnold J. Repta
IPC分类号： A61K9/00 , A61K9/70 , A61K31/42 , A61K31/4439 , A61K31/4545 , A61N1/30
CPC分类号： A61K31/4545 , A61K31/42 , A61K31/4439 , A61K9/0009
摘要： This invention relates to novel methods and devices for iontophoretically administering therapeutic doses of cell adhesion receptor antagonists in a controlled manner through the skin. Such antagonist compounds include but are not limited to antagonists of the IIb/IIIa and .alpha..sub.v .beta..sub.3 integrins and related cell surface adhesive protein receptors. The present invention includes iontophoretic delivery devices comprising cell adhesion receptor antagonists. Such methods and devices are useful, alone or in combination with other therapeutic agents, for the treatment of thromboembolic disorders, angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.
摘要翻译：本发明涉及以受控方式通过皮肤离子电渗施用治疗剂量的细胞粘附受体拮抗剂的新方法和装置。这种拮抗剂化合物包括但不限于IIb / IIIa和αvβ3整联蛋白和相关细胞表面粘附蛋白受体的拮抗剂。本发明包括包含细胞粘附受体拮抗剂的离子电渗疗法递送装置。这些方法和装置单独或与其它治疗剂组合用于治疗血栓栓塞障碍，血管生成障碍，炎症，骨退化，癌转移，糖尿病性视网膜病变，再狭窄，黄斑变性和由细胞粘附介导的其它病症， /或细胞迁移和/或血管发生。

9. 发明授权

US4757062A Substituted benzoate ester prodrugs of estrogens 失效
标题翻译：取代的苯甲酸酯前体药的雌激素
公开(公告)号：US4757062A
公开(公告)日：1988-07-12
申请号：US793892
申请日：1985-11-01
申请人： Bruce J. Aungst , Munir A. Hussain
发明人： Bruce J. Aungst , Munir A. Hussain
IPC分类号： A61K31/565 , C07J1/00 , C07J41/00 , A61K31/56
CPC分类号： C07J1/007 , C07J1/0096 , C07J41/0072
摘要： Substituted benzoate ester prodrugs of .beta.-estradiol and ethynyl estradiol are provided which have improved bioavailability and extended duration of action when administered orally.
摘要翻译：提供β-雌二醇和乙炔基雌二醇的取代的苯甲酸酯前药，其口服施用时具有改善的生物利用度和延长的作用持续时间。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式